Research Insights Episodes

This special episode of RealTalk MS is sponsored by EMD Serono and is only intended for a U.S. audience. EMD Serono is the healthcare business of Merck, KGaA, Darmstadt, Germany, in the United States and Canada. In this special episode of RealTalk MS, we're exploring what the invisible symptoms of MS are, and how to best empower people living with MS to talk about them with their healthcare team. Professor Klaus Schmierer is a Professor of Neurology at the Blizard Institute, Queen Mary's Unive...

Cognitive dysfunction is a common symptom of multiple sclerosis, affecting more than half of the people living with MS. While cognitive issues like changes in memory, difficulty maintaining attention, slower information processing speed and executive function may not be among the most disabling symptoms of MS, they may be among the most disconcerting symptoms. Whether it's your short-term memory, the ability to find your way to a familiar destination that you've gone to hundreds of times, or yo...

Chris Holland had a successful career working as a paralegal when he was diagnosed with MS in 2004. And, while everyone reacts differently to being diagnosed with MS, no one could have predicted what happened next, as Chris lost everything battling demons he never imagined he would ever face. But it would be a mistake betting against Chris Holland's resilience. Bouncing back, Chris decided to pursue his lifelong dream of becoming a chef. Today, Chris is a three-time Food Network Chopped champio...

With more than 9,000 MS researchers and clinicians in attendance, the 2023 combined ECTRIMS-ACTRIMS meeting in Milan was the largest MS research conference in the world. During the meeting, I had an opportunity to talk with some of the best and brightest minds in MS research and clinical practice. This is your invitation to listen in on my ECTRIMS EXTRA conversation with Dr. Robert Motl. Dr. Motl is a professor in the department of Kinesiology and Nutrition, and a professor in the department o...

With more than 9,000 MS researchers and clinicians in attendance, the 2023 combined ECTRIMS-ACTRIMS meeting in Milan was the largest MS research conference in the world. During the meeting, I had an opportunity to talk with some of the best and brightest minds in MS research and clinical practice. This is your invitation to listen in on my ECTRIMS EXTRA conversation with Dr. Daniel Ontaneda. Dr. Ontaneda is a neurologist at the Cleveland Clinic Neurological Institute's Mellen Center for Multip...

With more than 9,000 MS researchers and clinicians in attendance, the 2023 combined ECTRIMS-ACTRIMS meeting in Milan was the largest MS research conference in the world. During the meeting, I had an opportunity to talk with some of the best and brightest minds in MS research and clinical practice. This is your invitation to listen in on my ECTRIMS EXTRA conversation with Dr. Annette Langer-Gould. Dr. Langer-Gould is an MS Specialist at Kaiser-Permanente, and while at the ECTRIMS-ACTRIMS meetin...

With more than 9,000 MS researchers and clinicians in attendance, the 2023 combined ECTRIMS-ACTRIMS meeting in Milan was the largest MS research conference in the world. During the meeting, I had an opportunity to talk with some of the best and brightest minds in MS research and clinical practice. This is your invitation to listen in on my ECTRIMS EXTRA conversation with Dr. Anthony Feinstein. Dr. Feinstein is a Professor of Psychiatry at the University of Toronto, and his expertise is in the ...

This week, we're sharing more from the 2023 joint ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) and ACTRIMS (Americas Committee for Treatment and Research in Multiple Sclerosis) annual meeting. What if we could identify MS before anyone experienced any of the typical clinical symptoms? Would treating that person with a high-efficacy disease-modifying therapy prevent the clinical symptoms of MS from even developing? Those are the questions that make the study of t...

Last week, more than 9,000 MS research scientists and clinicians from more than 110 countries traveled to Milan to attend the largest MS research conference in the world, the 2023 joint ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) and ACTRIMS (Americas Committee for Treatment and Research in Multiple Sclerosis) annual meeting. In keeping with a RealTalk MS tradition, just as the meeting was ending and the thousands of attendees were heading for the exits, I conn...

We've been using the same MS clinical course descriptors (relapsing-remitting, secondary progressive, and primary progressive) for almost three decades. As research has provided so much additional information and insight, is it time to update the way we describe, diagnose, and treat MS? The International Advisory Committee on Clinical Trials in Multiple Sclerosis has established a working group to explore this question. And, as a means of eliciting feedback from stakeholders around the world, a...